CoChat

Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy

Open access
Tricarico, Pierre, Chardin, David, Martin, Nicolas, Contu, Sara, Hugonnet, Florent, Otto, Josiane, Humbert, Olivier · 2024 · Journal for ImmunoTherapy of Cancer

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Purpose: Because of atypical response imaging patterns in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs), new biomarkers are needed for a better monitoring of treatment efficacy. The aim of this prospective study was to evaluate the prognostic value of volume-derived positron-emission tomography (PET) parameters on baseline and follow-up 18 F-fluoro-deoxy-glucose PET ( 18 F-FDG-PET) scans and compare it with the conventional PET Response Criteria in Solid Tumors (PERCIST). Methods: Patients with metastatic NSCLC were included in two different single-center prospective trials. 18 F-FDG-PET studies were performed before the start of immunotherapy (PET baseline ), after 6–8 weeks (PET interim 1) and after 12–16 weeks (PET interim 2) of treatment, using PERCIST criteria for tumor response assessment. Different metabolic parameters were evaluated: absolute values of maximum standardized uptake value (SUVmax) of the most intense lesion, total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), but also their percentage changes between PET studies (ΔSUVmax, ΔTMTV and ΔTLG). The median follow-up of patients was 31 (7.3–31.8) months. Prognostic values and optimal thresholds of PET parameters were estimated by ROC (Receiver Operating Characteristic) curve analysis of 12-month overall survival (12M-OS) and 6-month progression-free survival (6M-PFS). Tumor progression needed to be confirmed by a multidisciplinary tumor board, considering atypical response patterns on imaging. Results: 110 patients were prospectively included. On PET baseline , TMTV was predictive of 12M-OS [AUC (Area Under Curve) =0.64; 95% CI: 0.61 to 0.66] whereas SUVmax and TLG were not. On PET interim 1 and PET interim 2, all metabolic parameters were predictive for 12M-OS and 6M-PFS, the residual TMTV on PET interim 1 (TMTV 1 ) being the strongest prognostic biomarker (AUC=0.83 and 0.82; 95% CI: 0.74 to 0.91, for 12M-OS and 6M-PFS, respectively). Using the optimal threshold by ROC curve to classify patients into three TMTV 1 subgroups (0 cm 3 ; 0–57 cm 3 ; >57 cm 3 ), TMTV 1 prognostic stratification was independent of PERCIST criteria on both PFS and OS, and significantly outperformed them. Subgroup analysis demonstrated that TMTV 1 remained a strong prognostic biomarker of 12M-OS for non-responding patients (p=0.0003) according to PERCIST criteria. In the specific group of patients with PERCIST progression on PET interim 1, low residual tumor volume (<57 cm 3 ) was still associated with a very favorable patients’ outcome (6M-PFS=73%; 24M-OS=55%). Conclusion: The absolute value of residual metabolic tumor volume, assessed 6–8 weeks after the start of ICPI, is an optimal and independent prognostic measure, exceeding and complementing conventional PERCIST criteria. Oncologists should consider it in patients with first tumor progression according to PERCIST criteria, as it helps identify patients who benefit from continued treatment. Trial registration number: 2018-A02116-49; NCT03584334 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2023-007628

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow-chart. ICPIs, immune checkpoint inhibitors; NSCLC, non-small-cell lung cancers; PET, positron-emission tomography.
Figure 1 Flow-chart. ICPIs, immune checkpoint inhibitors; NSCLC, non-small-cell lung cancers; PET, positron-emission tomography.CC BY-NC · PubMed Central
Figure 2 ROC curves figures of metabolic parameters at PETbaseline, PETinterim1 and PETinterim2, to predict 6 months PFS and 12 months OS. OS, overall survival; AUC, Area Under Curve; PET, positron-emission tomography; PFS, progression-free survival; ROC, Receiver Operating Characteristic; SUV, standardized uptake value; TLG, total lesion glycolysis; TMTV, total metabolic tumor volume.
Figure 2 ROC curves figures of metabolic parameters at PETbaseline, PETinterim1 and PETinterim2, to predict 6 months PFS and 12 months OS. OS, overall survival; AUC, Area Under Curve; PET, positron-emission tomography; PFS, progression-free survival; ROC, Receiver Operating Characteristic; SUV, standardized uptake value; TLG, total lesion glycolysis; TMTV, total metabolic tumor volume.CC BY-NC · PubMed Central
Figure 3 Progression-free survival (A) and overall survival (B) according to TMTV1. MTV, metabolic tumor volume; TMTV, total metabolic tumor volume.
Figure 3 Progression-free survival (A) and overall survival (B) according to TMTV1. MTV, metabolic tumor volume; TMTV, total metabolic tumor volume.CC BY-NC · PubMed Central
Figure 4 Progression-free survival (A) and overall survival (B) according to PERCIST evaluation at PETinterim1. CMR, complete metabolic response; PET, positron-emissiontomography; PERCIST, PET Response Criteria in Solid Tumors; PMD, progressive metabolic disease; PMR partial metabolic response; SMD stable metabolic disease.
Figure 4 Progression-free survival (A) and overall survival (B) according to PERCIST evaluation at PETinterim1. CMR, complete metabolic response; PET, positron-emissiontomography; PERCIST, PET Response Criteria in Solid Tumors; PMD, progressive metabolic disease; PMR partial metabolic response; SMD stable metabolic disease.CC BY-NC · PubMed Central
Figure 5 Progression-free survival and overall survival in PERCIST PMD subgroup on PETinterim1 according to TMTV1. PET, positron-emissiontomography; PERCIST, PET Response Criteria in Solid Tumors; PMD, progressive metabolic disease; TMTV, total metabolic tumor volume.
Figure 5 Progression-free survival and overall survival in PERCIST PMD subgroup on PETinterim1 according to TMTV1. PET, positron-emissiontomography; PERCIST, PET Response Criteria in Solid Tumors; PMD, progressive metabolic disease; TMTV, total metabolic tumor volume.CC BY-NC · PubMed Central
Figure 6 MIP images showing the tumorous evolution of a patient having a progressive disease according to PET Response Criteria in Solid Tumors (right pulmonary tumor) but a low residual total metabolic tumor volume1 (<57 cm3) at PETinterim1. PETinterim2 image shows a delayed decrease in tumorous burden. These low volume progressing patients could benefit from treatment continuation. MIP, maximum intensity projection; PET, positron-emission tomography.
Figure 6 MIP images showing the tumorous evolution of a patient having a progressive disease according to PET Response Criteria in Solid Tumors (right pulmonary tumor) but a low residual total metabolic tumor volume1 (<57 cm3) at PETinterim1. PETinterim2 image shows a delayed decrease in tumorous burden. These low volume progressing patients could benefit from treatment continuation. MIP, maximum intensity projection; PET, positron-emission tomography.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 5

  1. Seymour, 2017, iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, 18, e143, 10.1016/s1470-2045(17)30074-8 · DOI · Paper page
  2. Nabet, 2020, Noninvasive early identification of therapeutic benefit from immune Checkpoint inhibition, Cell, 183, 363, 10.1016/j.cell.2020.09.001 · DOI · Paper page
  3. Im, 2013, Usefulness of combined metabolic–volumetric indices of 18F-FDG PET/CT for the early prediction of neoadjuvant chemotherapy outcomes in breast cancer, Nucl Med Mol Imaging, 47, 36, 10.1007/s13139-012-0181-5 · DOI
  4. Driessen, 2022, The impact of semiautomatic segmentation methods on metabolic tumor volume, intensity, and dissemination radiomics in 18 F-FDG PET scans of patients with classical Hodgkin lymphoma, J Nucl Med, 63, 1424, 10.2967/jnumed.121.263067 · DOI
  5. Capobianco, 2021, Deep-learning 18F-FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma, J Nucl Med, 62, 30, 10.2967/jnumed.120.242412 · DOI

Cited by

See all 40

Metadata

Authors
Tricarico, P., Chardin, D., Martin, N., Contu, S., Hugonnet, F., Otto, J., & Humbert, O.
Affiliations
  • Centre Antoine Lacassagne (FR)
  • Centre National de la Recherche Scientifique (FR)
  • Princess Grace Hospital Centre (MC)
Corresponding author
Tricarico, Pierre
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2024-04
Volume
12
Issue
4
Pages
e007628
ISSN
2051-1426 (ISSN-L)
OpenAlex
W4395014773
Cited by
38
References
37
Citations by year
2026: 16 · 2025: 19 · 2024: 3
FWCI
9.68
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
3IA cote d'azur (ANR-19-P3IA-0002)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
Keywords
total metabolic tumor volume, 18F-FDG PET/CT, metastatic non-small cell lung cancer, immune checkpoint inhibitors, immunotherapy response monitoring, prognostic factors, PERCIST criteria, SUVmax, total lesion glycolysis, overall survival, progression-free survival, treatment response prediction, treatment toxicity prediction, treatment de-escalation
MeSH terms
Positron Emission Tomography Computed Tomography, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Neoplasm Metastasis, Prospective Studies, Fluorodeoxyglucose F18, Tumor Burden

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy. https://app.cochat.ai/papers/10.1136/jitc-2023-007628
The paper
Tricarico, P., Chardin, D., Martin, N., Contu, S., Hugonnet, F., Otto, J., & Humbert, O. (2024). Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007628

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.